| Literature DB >> 24078913 |
A F Adeniyi1, A E Uloko, O O Ogwumike, A O Sanya, A A Fasanmade.
Abstract
Gender is a major determinant of the outcomes of many health interventions. This study documents the order of significant improvements in metabolic parameters of patients with type 2 diabetes mellitus (T2DM) having metabolic syndrome within 12 weeks of physical exercise programmes. Twenty-nine patients, mean age 49.6 ± 3.7 years, presenting with high fasting plasma glucose, high triglycerides, hypertension, and high waist circumference undertook a thrice weekly aerobic and endurance exercise programme in addition to their drugs and diet. Variables were assessed at baseline and end of every two weeks for twelve weeks. Compared with baseline, significant improvement (P < 0.05) in the metabolic parameters occurred in this order for the male participants: fasting glucose (2nd week), triglycerides and waist circumference (4th week), and systolic blood pressure (12th week). For the female participants, it was fasting glucose (4th week), triglycerides (6th week), and waist circumference (10th week). Regardless of the gender, fasting glucose was the first to improve significantly, followed by triglycerides. Hypertension did not improve significantly at all in the female participants as they may require more than twelve weeks of therapeutic exercise for any significant improvement in hypertension.Entities:
Mesh:
Year: 2013 PMID: 24078913 PMCID: PMC3773397 DOI: 10.1155/2013/310574
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Descriptive characteristics including medications of the participants by gender.
| Variable | Mean ± SD | Minimum | Maximum | 95% CI |
|---|---|---|---|---|
| Age (years) | ||||
| Male ( | 46.2 ± 3.7 | 32.0 | 56.0 | 39.0–47.0 |
| Female ( | 51.5 ± 6.4 | 28.0 | 67.0 | 41.0–55.0 |
| Length of diagnosis | ||||
| Male ( | 4.9 ± 1.6 | 0.5 | 8.0 | 2.0–5.0 |
| Female ( | 7.7 ± 2.0 | 0.8 | 11.0 | 1.2–7.8 |
|
| ||||
| *Medications | ||||
| Number of medications at baseline | Medications at baseline | |||
|
| ||||
| Diabetes medications | ||||
| 3 males, 5 Females | 3 | Metformin, glimepiride, insulin | ||
| 5 males, 11 Females | 2 | Metformin, glimepiride, | ||
| 5 Females | 3 | Metformin, glyburide, insulin | ||
| Lipid medications | ||||
| 14 females | 2 | Atorvastatin, fenofibrate | ||
| 5 males, 4 females | 1 | Atorvastatin | ||
| 3 males, 3 females | 1 | Fenofibrate | ||
| Blood pressure medications | ||||
| 6 males, 9 females | 2 | Amlodipine, valsartan | ||
| 2 males, 5 females | 2 | Lisinopril, bendrofluazide | ||
| 7 females | 2 | Hydrochlorothiazide losartan | ||
|
| ||||
| Known complications | ||||
| Number of complications | Types of complications | |||
|
| ||||
| 3 males, 5 females | 3 | Nephropathy, PN, PAD | ||
| 4 males, 12 females | 1 | PN | ||
| 4 females | 4 | IHD, PN, nephropathy, PAD | ||
Key: IHD: ischaemic heart disease; PN: peripheral neuropathy; PAD: peripheral arterial disease.
*Types of medications were in various combinations based on the physician's assessment of the need of individual patient and in response to the exercise programme; downward adjustments were made in combinations or dosages as deemed necessary by the physician. There was no upward review of dosage or combinations throughout the study period.
Clinical profile of the participants at baseline by gender.
| Variable | Mean ± SD | Minimum | Maximum | 95% CI |
|---|---|---|---|---|
| Fasting plasma glucose (mmol/L) | ||||
| Male ( | 8.9 ± 2.1 | 2.0 | 18.0 | 6.6–8.0 |
| Female ( | 10.6 ± 3.9 | 3.0 | 22.0 | 9.4–11.9 |
| HBA1c (%) | ||||
| Male ( | 8.79 ± 2.69 | 6.38 | 11.06 | 8.22–9.14 |
| Female ( | 10.08 ± 1.72 | 7.20 | 13.60 | 9.55–10.61 |
| Body mass index (Kg/m2) | ||||
| Male ( | 29.6 ± 5.4 | 23.5 | 52.4 | 29.3–38.8 |
| Female ( | 35.8 ± 6.9 | 26.1 | 57.3 | 31.5–39.9 |
| Waist circumference (cm) | ||||
| Male ( | 103.1 ± 11.1 | 75.0 | 141.0 | 98.5–106.8 |
| Female ( | 96.5 ± 8.6 | 76.0 | 101.0 | 89.2–98.6 |
| Waist hip ratio | ||||
| Male ( | 0.95 ± 0.05 | 0.88 | 1.03 | 0.95–0.97 |
| Female ( | 0.91 ± 0.02 | 0.83 | 0.95 | 0.85–0.89 |
| Percent body fat (%) | ||||
| Male ( | 33.24 ± 5.28 | 22.30 | 42.70 | 30.87–36.33 |
| Female ( | 37.91 ± 4.78 | 18.70 | 47.80 | 26.16–40.94 |
| High density lipoprotein (mmol/L) | ||||
| Male ( | 0.76 ± 0.23 | 0.65 | 1.60 | 0.62–0.86 |
| Female ( | 0.71 ± 0.35 | 0.58 | 1.86 | 0.66–0.84 |
| Low density lipoprotein (mmol/L) | ||||
| Male ( | 3.92 ± 0.79 | 1.30 | 5.60 | 3.53–4.02 |
| Female ( | 4.35 ± 1.10 | 1.58 | 6.37 | 2.74–4.82 |
| Total cholesterol (mmol/L) | ||||
| Male ( | 7.17 ± 1.52 | 2.90 | 9.60 | 6.70–7.64 |
| Female ( | 8.22 ± 1.97 | 1.52 | 9.86 | 4.18–6.72 |
| Triglyceride (mmol/L) | ||||
| Male ( | 1.9 ± 0.3 | 1.0 | 2.3 | 1.6–2.1 |
| Female ( | 2.3 ± 0.5 | 1.2 | 3.1 | 1.8–2.6 |
| Systolic blood pressure (mmHg) | ||||
| Male ( | 165.0 ± 7.50 | 140.00 | 190.00 | 156.5–170.5 |
| Female ( | 160.0 ± 6.00 | 120.00 | 210.00 | 140.0–180.0 |
| Diastolic blood pressure (mmHg) | ||||
| Male ( | 90.00 ± 8.30 | 75.00 | 110.00 | 80.0–95.0 |
| Female ( | 90.00 ± 10.5 | 80.00 | 100.00 | 90.0–95.0 |
Figure 1Changes in the mean values of the metabolic parameters by gender across the 12 weeks of exercise programme (all shown with standard errors).
First significant changes in metabolic parameters by gender (reassessment values compared with baseline).
| Second week | Forth week | Sixth week | Eighth week | Tenth week | Twelfth week | |
|---|---|---|---|---|---|---|
| Sex | ||||||
| Male ( | Fasting glucose | Triglycerides | Systolic blood pressure | |||
| Female ( | Fasting glucose | Triglycerides | Waist circumference |